Search Results



Your search for S. Vincent Rajkumar, MD matches 13 pages

Showing 1 - 13


multiple myeloma

S. Vincent Rajkumar, MD, and Sagar Lonial, MD, on Treating Multiple Myeloma

S. Vincent Rajkumar, MD, of the Mayo Clinic, and Sagar Lonial, MD, of the Emory University School of Medicine, discuss key issues in treating this disease, including monoclonal antibodies, plasmacytoma, and plasma cell leukemia.

multiple myeloma

Ixazomib: A Relevant Addition to Myeloma Therapy

In 2015, four new drugs were approved for the treatment of multiple myeloma by the U.S. Food and Drug Administration: panobinostat (Farydak), daratumumab (Darzalex), elotuzumab (Empliciti), and ixazomib (Ninlaro). Of them, the first three are drugs with unique new targets, whereas ixazomib is the...

multiple myeloma

The ENDEAVOR Trial: A Case Study in the Interpretation of Modern Cancer Trials

It can be easy to miss the forest for the trees in the interpretation of clinical trials. In particular, trials for the treatment of cancer are exceedingly complex, with long lists of inclusion and exclusion criteria, designs with hidden biases, drugs with unpronounceable names (if not cumbersome...

multiple myeloma

Multiple Myeloma in 2015: A Year for the Record Books

Few malignancies have received as much attention, in the way of newly approved drugs, as multiple myeloma did in 2015. In November alone, 3 new agents were approved, bringing the total to 4 for the year as part of a record 7 approvals and to 16 regulatory approvals over the past 12 years. Speakers ...

multiple myeloma

Maintenance Therapy in Multiple Myeloma

In 2012, three randomized placebo-controlled trials reported a significant prolongation of progression-free survival with lenalidomide (Revlimid) as maintenance therapy for multiple myeloma.1-3 Two of these trials tested lenalidomide maintenance after stem cell transplantation, and one investigated ...

multiple myeloma

Treatment of Newly Diagnosed Multiple Myeloma With Lenalidomide Plus Low-Dose Dexamethasone

The FIRST trial—reported by Benboubker and colleagues in The New England Journal of Medicine and summarized in this issue of The ASCO Post (page 93)—is a landmark study.1 It is one of the largest randomized trials in multiple myeloma ever conducted. More importantly, it is a well-designed trial...

multiple myeloma

Elotuzumab Ushers in a New Era in Myeloma Therapy

The long wait for monoclonal antibodies for the treatment of multiple myeloma is over. In the landmark ELOQUENT-2 study, reviewed in this issue of The ASCO Post, Lonial and colleagues convincingly demonstrate the effectiveness of elotuzumab, a monoclonal antibody directed against SLAMF7, in the...

cost of care

Making Their Voices Heard: 118 Oncologists Speak Out About Stemming the High Cost of Cancer Drugs

In a bold move to shed light on the ramifications of the ever-increasing cost of cancer drugs for patients with cancer and for the health-care system, 118 prominent oncologists came together to write a commentary in Mayo Clinic Proceedings detailing their concerns.1 To learn more about these...

Equanimity

The following essay by S. Vincent Rajkumar, MD, is adapted from The Big Casino: America’s Best Cancer Doctors Share Their Most Powerful Stories, which was coedited by Stan Winokur, MD, and Vincent Coppola and published in May 2014. The book is available on Amazon.com and thebigcasino.org. It was...

hematologic malignancies

The State of Progress in Hematologic Malignancies

The number of targeted therapies approved by the U.S. Food and Drug Administration (FDA) in the treatment of a variety of cancers, especially hematologic malignancies, continues to rise. In 2014 alone, 4 of the 10 new agents directed at discrete molecular targets approved by the FDA were for blood...

multiple myeloma

S. Vincent Rajkumar, MD, on Multiple Myeloma: Newly Approved Drugs

S. Vincent Rajkumar, MD, of the Mayo Clinic, summarizes a special FDA-sponsored session on the three myeloma drugs that were approved this November––daratumumab, ixazomib, and elotozumab––and their current and future roles in treating the disease.

multiple myeloma

S. Vincent Rajkumar, MD, on Advances in Myeloma

S. Vincent Rajkumar, MD, of the Mayo Clinic, summarizes his education session on the evolving diagnostic criteria for myeloma, which focused on smoldering disease and when it becomes an “open flame.”

issues in oncology
issues in oncology
issues in oncology
cost of care

Experts Explore the Reasons Behind the High Cost of Cancer Drugs in America

Increasingly high prices for cancer drugs are affecting patient care, as well as the health-care system overall, in the United States. These findings were published in a special article by Rajkumar and Kantarjian in the journal Mayo Clinic Proceedings. “Americans with cancer pay 50% to 100%...

Advertisement



Advertisement


Advertisement